Info Pulse Now

HOMEcorporatetechentertainmentresearchmiscwellnessathletics

Wellington Management Group LLP Has $37.80 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)


Wellington Management Group LLP Has $37.80 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Wellington Management Group LLP raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 35.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 74,811 shares of the company's stock after acquiring an additional 19,663 shares during the quarter. Wellington Management Group LLP owned about 0.09% of IDEXX Laboratories worth $37,796,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in IDEXX Laboratories by 0.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company's stock worth $379,875,000 after purchasing an additional 2,463 shares during the period. American Century Companies Inc. raised its stake in IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock worth $274,179,000 after buying an additional 177,226 shares during the period. International Assets Investment Management LLC lifted its holdings in IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after acquiring an additional 527,460 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in IDEXX Laboratories by 13.1% in the second quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company's stock valued at $249,855,000 after acquiring an additional 59,519 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of IDEXX Laboratories by 4.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 406,086 shares of the company's stock worth $205,163,000 after acquiring an additional 15,521 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

IDXX has been the subject of a number of research reports. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target for the company. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Barclays reduced their target price on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus target price of $539.63.

Read Our Latest Analysis on IDXX

In other news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now directly owns 905 shares of the company's stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.11% of the company's stock.

IDXX opened at $437.18 on Friday. The firm has a market cap of $35.80 billion, a P/E ratio of 42.16, a price-to-earnings-growth ratio of 3.98 and a beta of 1.37. The business's fifty day moving average is $441.39 and its 200-day moving average is $472.64. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to analysts' expectations of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm's quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the firm posted $2.53 earnings per share. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider IDEXX Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.

While IDEXX Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

Previous articleNext article

POPULAR CATEGORY

corporate

9808

tech

8831

entertainment

12396

research

5854

misc

13000

wellness

10208

athletics

13170